Test–retest reliability of arterial spin labelling for cerebral blood flow in older adults with small vessel disease

Translational Stroke Research - Tập 13 - Trang 583-594 - 2022
Lauren R. Binnie1, Mathilde M. H. Pauls1,2, Philip Benjamin1,3, Mohani-Preet K. Dhillon1, Shai Betteridge4, Brian Clarke2, Rita Ghatala2, Fearghal A. H. Hainsworth1, Franklyn A. Howe1, Usman Khan2, Christina Kruuse5, Jeremy B. Madigan3, Barry Moynihan2,6, Bhavini Patel2, Anthony C. Pereira2, Egill Rostrup7, Anan B. Y. Shtaya1, Catherine A. Spilling1, Sarah Trippier8, Rebecca Williams8, Jeremy D. Isaacs1,2, Thomas R. Barrick1, Atticus H. Hainsworth1,2
1Molecular & Clinical Sciences Research Institute, St George’s University of London, London, UK
2Department of Neurology, St George’s University Hospitals NHS Foundation Trust London, London, UK
3Department of Neuroradiology, St George’s University Hospitals NHS Foundation Trust London, London, UK
4Department of Neuropsychology, St George’s University Hospitals NHS Foundation Trust London, London, UK
5Department of Neurology and Neurovascular Research Unit, Herlev Gentofte Hospital, Herlev, Denmark
6Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
7Mental Health Centre, University of Copenhagen, Glostrup, Denmark
8South London Stroke Research Network, St George’s Hospital, London, UK

Tóm tắt

Cerebral small vessel disease (SVD) is common in older people and is associated with lacunar stroke, white matter hyperintensities (WMH) and vascular cognitive impairment. Cerebral blood flow (CBF) is reduced in SVD, particularly within white matter. Here we quantified test–retest reliability in CBF measurements using pseudo-continuous arterial spin labelling (pCASL) in older adults with clinical and radiological evidence of SVD (N=54, mean (SD): 66.9 (8.7) years, 15 females/39 males). We generated whole-brain CBF maps on two visits at least 7 days apart (mean (SD): 20 (19), range 7-117 days). Test–retest reliability for CBF was high in all tissue types, with intra-class correlation coefficient [95%CI]: 0.758 [0.616, 0.852] for whole brain, 0.842 [0.743, 0.905] for total grey matter, 0.771 [0.636, 0.861] for deep grey matter (caudate-putamen and thalamus), 0.872 [0.790, 0.923] for normal-appearing white matter (NAWM) and 0.780 [0.650, 0.866] for WMH (all p<0.001). ANCOVA models indicated significant decline in CBF in total grey matter, deep grey matter and NAWM with increasing age and diastolic blood pressure (all p<0.001). CBF was lower in males relative to females (p=0.013 for total grey matter, p=0.004 for NAWM). We conclude that pCASL has high test–retest reliability as a quantitative measure of CBF in older adults with SVD. These findings support the use of pCASL in routine clinical imaging and as a clinical trial endpoint. All data come from the PASTIS trial, prospectively registered at: https://eudract.ema.europa.eu (2015-001235-20, registered 13/05/2015), http://www.clinicaltrials.gov (NCT02450253, registered 21/05/2015).

Tài liệu tham khảo